Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.

Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML, Chinni SR.

Transl Oncol. 2010 Jun 1;3(3):195-203.

2.

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR.

Mol Cancer Res. 2013 Nov;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705.

3.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176.

4.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75.

5.

Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.

Yin L, Rao P, Elson P, Wang J, Ittmann M, Heston WD.

PLoS One. 2011;6(6):e21319. doi: 10.1371/journal.pone.0021319.

6.

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.

Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, Budäus L, Albrecht H, Akslen LA, Schlomm T, Kalland KH.

APMIS. 2009 Aug;117(8):575-82. doi: 10.1111/j.1600-0463.2009.02517.x.

PMID:
19664128
7.

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML.

Prostate. 2006 Jan 1;66(1):32-48.

PMID:
16114056
8.
9.

Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis.

Mochizuki H, Matsubara A, Teishima J, Mutaguchi K, Yasumoto H, Dahiya R, Usui T, Kamiya K.

Biochem Biophys Res Commun. 2004 Jul 30;320(3):656-63.

PMID:
15240098
10.

Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.

Winnes M, Lissbrant E, Damber JE, Stenman G.

Oncol Rep. 2007 May;17(5):1033-6.

PMID:
17390040
11.

Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.

Cancer Res. 2009 Jan 15;69(2):640-6. doi: 10.1158/0008-5472.CAN-08-2008.

12.

Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.

Tian TV, Tomavo N, Huot L, Flourens A, Bonnelye E, Flajollet S, Hot D, Leroy X, de Launoit Y, Duterque-Coquillaud M.

Oncogene. 2014 Apr 24;33(17):2204-14. doi: 10.1038/onc.2013.176.

PMID:
23708657
13.

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Cai C, Wang H, Xu Y, Chen S, Balk SP.

Cancer Res. 2009 Aug 1;69(15):6027-32. doi: 10.1158/0008-5472.CAN-09-0395.

14.

Establishment of CXCR4-small interfering RNA retrovirus vector driven by human prostate-specific antigen promoter and its biological effects on prostate cancer in vitro and in vivo.

Du YF, Shi Y, Xing YF, Zeng FQ.

J Cancer Res Clin Oncol. 2008 Nov;134(11):1255-64. doi: 10.1007/s00432-008-0394-2. Erratum in: J Cancer Res Clin Oncol. 2008 Nov;134(11):1265. Xing, Yi-fei [corrected to Xing, Yi-Fei]; Zeng, Fu-qing [corrected to Zeng, Fu-Qing].

PMID:
18431597
15.

CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Singh S, Singh UP, Grizzle WE, Lillard JW Jr.

Lab Invest. 2004 Dec;84(12):1666-76.

16.

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A.

Cancer Biol Ther. 2007 Jan;6(1):40-5.

PMID:
17172822
17.

A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR.

Mod Pathol. 2007 Apr;20(4):467-73.

19.

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096.

PMID:
20303538
Items per page

Supplemental Content

Support Center